Our Science

Highly targeted and tumor-agnostic aproach for treating cancer

The flexible synthetic design of the MAC-TAC platform allows for the development of a broad range of pan-cancer molecules with the potential to deliver superior safety and efficacy.

Resolute Science has developed a groundbreaking, highly targeted, and tumor-agnostic approach for treating cancer.

Our proprietary platform leverages the body’s natural tumor-associated macrophages (TAMs) to deliver toxic payloads to cancer cells.

Tumor-associated macrophages (TAMs) contribute to various stages of cancer development and occupy up to 50% of a tumor’s cell mass, making them a strategic target for our innovative approach.

Resolute’s novel drug class, Macrophage Targeted Conjugates (MAC-TACs), takes advantage of the normal behavior and cellular machinery of TAMs to deliver toxic payloads to adjacent cancer cells.

Our modular MAC-TAC platform is engineered for precision. The design accommodates different anti-cancer payloads, enabling versatility in treatment options. This unique strategy sets Resolute apart in the field of cancer therapeutics, providing a unique and versatile strategy for combating multiple cancer types.